









Markets
/
Stocks
/
nasdaq-maze
/

Maze Therapeutics Inc

MAZE

30.380USD

-1.330-4.19%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

1.33BMarket Cap

LossP/E TTM



Maze Therapeutics Inc

30.380

-1.330-4.19%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Maze Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Maze Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 37 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Maze Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

37 / 391

Overall Ranking

134 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Maze Therapeutics Inc Highlights

StrengthsRisks

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -9.96, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 40.80M shares, increasing 2.26% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 114.66K shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

65.500

Target Price

+33.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Maze Therapeutics Inc is 7.84, ranking 64 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.47

Change

0.37



Financials

9.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.57

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Maze Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Maze Therapeutics Inc is 6.70, ranking 232 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.96, which is -2159.43% below the recent high of 205.07 and -103.46% above the recent low of -20.26.

Score

Industry at a Glance

Previous score

6.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 37/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Maze Therapeutics Inc is 9.00, ranking 19 out of 391 in the Biotechnology & Medical Research industry. The average price target is 39.50, with a high of 60.00 and a low of 34.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

65.500

Target Price

+106.56%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Maze Therapeutics Inc

MAZE

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Maze Therapeutics Inc is 6.78, ranking 135 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 46.30 and the support level at 21.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.85

Change

-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-4.589

Sell

RSI(14)

24.820

Sell

STOCH(KDJ)(9,3,3)

10.588

Oversold

ATR(14)

4.858

Low Volatility

CCI(14)

-175.945

Sell

Williams %R

95.009

Oversold

TRIX(12,20)

-0.262

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

38.364

Sell

MA10

43.940

Sell

MA20

45.720

Sell

MA50

45.483

Sell

MA100

41.615

Sell

MA200

30.354

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Maze Therapeutics Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 84.78%, representing a quarter-over-quarter increase of 1.45%. The largest institutional shareholder is The Vanguard, holding a total of 1.70M shares, representing 3.53% of shares outstanding, with 131.73% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Third Rock Ventures, LLC

5.42M

-22.78%

Frazier Life Sciences Management, L.P.

4.57M

-0.00%

Deep Track Capital LP

3.95M

ARCH Venture Partners

4.12M

Janus Henderson Investors

751.87K

-46.34%

Andreessen Horowitz

1.70M

The Vanguard Group, Inc.

Star Investors

1.33M

+218.14%

BlackRock Institutional Trust Company, N.A.

1.20M

+112.74%

VR Adviser, LLC

1.23M

Alphabet, Inc.

2.41M

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Maze Therapeutics Inc is 5.31, ranking 47 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.